The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024.
EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM
Future Directions in the Management of Multiple Myeloma
ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone
EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma
Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024
Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024
Game-Changing Strategies for Early-Relapsed Myeloma
Future Indications and Frontline Potential of Cilta-Cel in Multiple Myeloma: Insights From Dr Binod Dhakal
Dr Binod Dhakal: The Importance of Patient Monitoring With Cilta-Cel Treatment
Dr Binod Dhakal Discusses Game-Changing Cilta-Cel Approval for RRMM
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma
Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM
Older, Younger Patients With MM Show Similar Outcomes With Teclistamab